Sanara MedTech Inc.

Sanara MedTech Inc. (SMTI) is a US-listed equity tracked across major market indices. Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.

The company reports trailing twelve-month revenue of $5.82M and net income of $458,957. Key metrics include a return on equity of 6.5%, a debt-to-equity ratio of 8.86.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for SMTI to support both active traders and long-term investors.